Global Genital Warts Market Assessment, By Drug Type [Imiquimod, Podophyllin and Podofilox, Trichloroacetic Acid, Sine Catechins, Isotretinoin, Others], By Treatment [Cryotherapy, Laser Removal, Surgical Removal, Topical Treatment], By Route of Administration [Oral, Parenteral], By End-user [Hospitals, Dermatology Centers, Research Centers, Others], By Region, Opportunities and Forecast, 2017-2031F

Genital warts market is expected to experience growth due to an increasing number of HPV leading to genital warts, advancing technology, and government initiatives like spreading awareness and providing free vaccines.

Home>Industry Reports>Global Genital Warts Market Assessment, Opportunities and Forecast, 2017-2031F

Global genital warts market is projected to witness a CAGR of 4.79% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 2.92 billion in 2031. The genital warts market is experiencing growth due to rising numbers of HPV cases, particularly in adults. In addition to government initiatives, advancing technology and efforts of R&D are also fueling the market greatly. HPV is seen to drastically rise in population all over the globe, leading to a rise in several genital warts cases as well. Technology is also advancing in terms of improved solutions to disease. The vaccine for HPV gives the body enough immunization to not let warts or other such STDs happen. The government is playing a major role in spreading awareness about getting vaccinations to avoid getting such diseases in the first place. Giving free vaccines in schools, and camps, and organizing rallies and camps to spread awareness are some of the government initiatives, which are offering lucrative market opportunities.

In Canada, a statement was passed by the Minister of Health, the Minister of Mental Health and Addictions, and the Associate Minister of Health on Human Papillomavirus Prevention Week. It stated that vaccination is one of the best methods to avoid cancer and genital warts. The HPV vaccination is available at no cost through school-based clinics, public health clinics, or catch-up programs. It is advised for 9 to 14-year-olds as part of their usual vaccination schedule.
The efforts underway to reach the national goal of 90% immunization among Canadian youth by 2025 are heartening. 84% of 14-year-olds received an HPV vaccination in 2021, a considerable increase in males' HPV vaccination rates over the two years prior. Even if this objective can be attained, it is crucial to keep advocating for and supporting HPV vaccination for all kids.

Download Free Sample Report

Increasing Prevalence of Genital Warts

Throughout the world, one of the most prevalent STDs is the genital warts caused due to human papillomavirus (HPV). While most HPV infections are benign and go away on their own, some virus strains can cause genital warts and several kinds of cancer. The global market for genital warts is expanding rapidly because of the growing interest in the creation of diagnostic instruments, vaccinations, and therapies due to the rising prevalence of HPV-related illnesses, including genital warts. Mortality rates have decreased because of early discovery and treatment made possible by routine screening with Pap smears and HPV testing. Highly contagious genital warts are known to be caused by HPV strains 6 and 11. They may not be fatal, but they can cause discomfort and reduce one's quality of life. The market for associated disorders with HPV, such as genital warts, is expected to increase significantly in the future as creative approaches to treating HPV-related illnesses become more and more in demand. There is hope that we may reduce the prevalence of such diseases and improve people's general health and well-being globally through ongoing research, immunization campaigns, and public awareness initiatives.

According to a study that was published in 2023 by The Lancet Global Health, nearly one in three men over the age of 15 have at least one genital human papillomavirus (HPV) type infection, and one in five have one or more of the high risks, or oncogenic, HPV kinds. These estimates highlight the significance of collaborative efforts to manage HPV infection and reduce the prevalence of HPV-related disease in both men and women. Such efforts are anticipated to increase market demand.

Technological Advancements

Better indication detection, treatment, and prevention have long been made possible by technological improvements in the healthcare sector. One such field is the treatment of diseases linked to the human papillomavirus (HPV), such as genital warts, where technology is having a big influence. Growing technological improvements have been a major factor in driving the global genital warts market in recent years. Developing more precise and accessible screening methods is one of the main ways that technology improvements are impacting the genital warts business. The main tools for identifying HPV and the disease associated with it have historically been Pap smears and HPV DNA testing. But more recent technologies have also surfaced, like molecular diagnostics and liquid-based cytology. The use of liquid-based cytology facilitates the identification of anomalies.

Conversely, molecular testing finds the virus' genetic makeup and yields more accurate results. These advanced screening techniques not only increase diagnosis accuracy, but also provide faster results.  The development of vaccinations that specifically target HPV strains has been made possible by developments in molecular biology and genetic sequencing. The development of the HPV vaccination has revolutionized the fight against cervical cancer, genital warts, and other related conditions. The goal of ongoing research and development is to increase the effectiveness of vaccines and increase their use.

Teva Pharmaceuticals launched the first generic version of Absorica (isotretinoin) in April 2021, intended to treat severe, resistant nodular acne genital warts. Oral isotretinoin is an effective therapy option for patients with resistant facial plane genital warts.

Topical Treatment Method is Dominating the Global Market

Over the course of the projection period, the topical treatment segment is expected to grow at a rapid rate. Topical treatment is successful in managing HPV infections. They provide patients with an all-encompassing approach to medical therapy by treating the underlying virus as well as the symptoms. These treatments work by destroying the warts and stimulating the body's immune system to fight the virus. Some commonly used topical treatments include imiquimod, podofilox, and sinecatechins. Imiquimod is an immune response modifier that stimulates the body's immune system to attack the virus and is applied directly to the affected area.

In March 2020, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. announced a collaboration and licensing agreement to create and commercialize product candidates, such as VP-102, for a topical cantharidin formulation intended to treat molluscum contagiosum and common genital warts in Japan.

North America to Dominate Genital Warts Market

With the biggest market share in terms of value, North America has emerged as the leading force in the global genital warts industry. The high incidence of HPV in the region is one of the main causes of North America's market domination in genital warts. Particularly in the United States, there is a significant HPV burden, with millions of new cases reported yearly. Due to the high prevalence, there is a sizable market for HPV-related goods and services due to the increasing demand for HPV diagnostic tests, vaccinations, and treatment options. Modern hospitals, cutting-edge diagnostic tools, and a highly qualified medical workforce are all part of North America's well-developed healthcare infrastructure. Efficient screening, diagnosis, and treatment of illnesses linked to HPV are made possible by this infrastructure. Moreover, with the state-of-the-art medical treatments and technologies, North America is the top choice for patients looking for HPV-related healthcare services that may include treatment of genital warts, cervical cancer, etc. According to the estimate by the Wahington State Department of Health, the prevalence of genital HPV is becoming more and more common, with 14 million newly Americans contracting the virus annually and 79 million Americans currently suffering from HPV infection.

Future Market Scenario (2024 – 2031F)

The growing need to address a variety of symptoms that occur due to the HPV strains, especially genital warts, is driving the market growth. With the advent of new and improved technologies and well researched new drugs and vaccines that are available to everyone, the market will surely see expansion. Treatments like that of laser and surgery are also growing in popularity. They are expensive but because they provide quicker and better results, people are opting for laser despite its high cost. Global healthcare governing bodies are also launching several awareness campaigns to increase awareness related to genital warts among the general population in emerging countries, which, in turn, is acting as a significant market trend.

Report Scope

“Genital Warts Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global genital warts market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute

Details

Base Year of the Analysis

2023

Historical Period

2017-2022

Forecast Period

2024-2031

Projected Growth Rate

CAGR of 4.79% between 2024 and 2031

Revenue Forecast in 2031

USD 2.92 billion

Segments Covered

Drug Type, Treatment, Route of Administration, End-user

Regions Covered

North America, Europe, South America, Asia-Pacific, Middle East and Africa

Key Companies Profile

Pfizer Inc., Sanofi Aventis LLC, Orgenesis Biotech Company, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Merck & Co., Inc, Cipla Ltd., GlaxoSmithKline Plc, Phio Pharmaceuticals Corp., Taro Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies, Inc.

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfill your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, the global genital warts market has been segmented into the following categories: 

·         By Drug Type

o   Imiquimod

o   Podophyllin and Podofilox

o   Trichloroacetic Acid

o   Sine Catechins

o   Isotretinoin

o   Others 

·         By Treatment

o   Cryotherapy

o   Laser Removal

o   Surgical Removal

o   Topical Treatment

·         By Route of Administration

o   Oral

o   Parenteral

·         By End-user

o   Hospitals

o   Dermatology Centers

o   Research Centers

o   Others

·         By Region

o   North America

o   Europe

o   Asia-Pacific

o   South America

o   Middle East and Africa

Key Players Landscape and Outlook

The global genital warts market is dominated by a few major players. Among the businesses that are presently governing the market shares are Pfizer Inc., Sanofi, Orgenesis biotech company, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Merck & Co., Inc, and Cipla Ltd. These companies are dominating the market due to their persistent efforts towards R&D, technological advancements, and reliable quality.

Affinivax, Inc. is a diagnostic biopharmaceutical firm based in Cambridge, Massachusetts. GSK plc agreed to buy it in May 2022 for a cash price of $2.1 billion, with an extra $1.2 billion possible if certain growth goals are met. Leading the charge in creating a cutting-edge pneumococcal vaccination for the future is Affinivax.

Eli Lilly and UNICEF signed a new partnership in September 2021 with the goal of improving health outcomes for 10 million children and adolescents with serious non-communicable diseases (NCDs) by 2025. Lilly has pledged $14.4 million as part of this cooperation to support UNICEF's ongoing initiatives in particular nations targeted at reducing NCD risk factors.

Key Players Operating in the Global Genital Warts Market are:

·         Pfizer Inc.

·         Sanofi Aventis LLC

·         Orgenesis Biotech Company

·         Teva Pharmaceutical Industries Ltd.

·         Verrica Pharmaceuticals

·         Merck & Co., Inc

·         Cipla Ltd.

·         GlaxoSmithKline Plc

·         Phio Pharmaceuticals Corp.

·         Taro Pharmaceutical Industries Ltd.

·         Mylan N.V.

·         Bausch Health Companies, Inc.

Markets and Data’s reports answer the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for the global genital warts market, you may approach our team at info@marketsandata.com

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Executive Summary

4.       Global Genital Warts Market Outlook, 2017-2031F

4.1.    Market Size & Forecast

4.1.1.By Value

4.1.2.By Volume

4.2.    By Drug Type

4.2.1.Imiquimod

4.2.2.Podophyllin and Podofilox

4.2.3.Trichloroacetic acid

4.2.4.Sine catechins

4.2.5.Isotretinoin

4.2.6.Others

4.3.    By Treatment

4.3.1.Cryotherapy

4.3.2.Laser removal

4.3.3.Surgical removal

4.3.4.Topical treatment

4.4.    By Route of Administration

4.4.1.Oral

4.4.2.Parenteral

4.5.    By End-user

4.5.1.Hospitals

4.5.2.Dermatology Centers

4.5.3.Research Centers

4.5.4.Others

4.6.    By Region

4.6.1.  North America

4.6.2.  Europe

4.6.3.  Asia-Pacific

4.6.4.  South America

4.6.5.  Middle East and Africa

4.7.    By Company Market Share (%), 2023

5.       Global Genital Warts Market Outlook, By Region, 2017-2031F

5.1.    North America*

5.1.1.Market Size & Forecast

5.1.1.1.              By Value

5.1.1.2.              By Volume

5.1.2.By Drug Type

5.1.2.1.              Imiquimod

5.1.2.2.              Podophyllin and Podofilox

5.1.2.3.              Trichloroacetic acid

5.1.2.4.              Sine catechins

5.1.2.5.              Isotretinoin

5.1.2.6.              Others

5.1.3.By Treatment

5.1.3.1.              Cryotherapy

5.1.3.2.              Laser removal

5.1.3.3.              Surgical removal

5.1.3.4.              Topical treatment

5.1.4.By Route of Administration

5.1.4.1.              Oral

5.1.4.2.              Parenteral

5.1.5.By End-user

5.1.5.1.              Hospitals

5.1.5.2.              Dermatology Centers

5.1.5.3.              Research Centers

5.1.5.4.              Others

5.1.6.United States*

5.1.6.1.              Market Size & Forecast

5.1.6.1.1.                    By Value

5.1.6.1.2.                    By Volume

5.1.6.2.              By Drug Type

5.1.6.2.1.                    Imiquimod

5.1.6.2.2.                    Podophyllin and Podofilox

5.1.6.2.3.                    Trichloroacetic acid

5.1.6.2.4.                    Sine catechins

5.1.6.2.5.                    Isotretinoin

5.1.6.2.6.                    Others

5.1.6.3.              By Treatment

5.1.6.3.1.                    Cryotherapy

5.1.6.3.2.                    Laser removal

5.1.6.3.3.                    Surgical removal

5.1.6.3.4.                    Topical treatment

5.1.6.4.              By Route of Administration

5.1.6.4.1.                    Oral

5.1.6.4.2.                    Parenteral

5.1.6.5.              By End-user

5.1.6.5.1.                    Hospitals

5.1.6.5.2.                    Dermatology Centers

5.1.6.5.3.                    Research Centers

5.1.6.5.4.                    Others

5.1.7.Canada

5.1.8.Mexico

*All segments will be provided for all regions and countries covered

5.2.    Europe

5.2.1.Germany

5.2.2.France

5.2.3.Italy

5.2.4.United Kingdom

5.2.5.Russia

5.2.6.Netherlands

5.2.7.Spain

5.2.8.Turkey

5.2.9.Poland

5.3.    Asia-Pacific

5.3.1.India

5.3.2.China

5.3.3.Japan

5.3.4.Australia

5.3.5.Vietnam

5.3.6.South Korea

5.3.7.Indonesia

5.3.8.Philippines

5.4.    South America

5.4.1.Brazil

5.4.2.Argentina

5.5.    Middle East & Africa

5.5.1.Saudi Arabia

5.5.2.UAE

5.5.3.South Africa

6.       Market Mapping, 2023

6.1.    By Drug Type

6.2.    By Route of Administration

6.3.    By Treatment

6.4.    By End-user

6.5.    By Region

7.       Macro Environment and Industry Structure

7.1.    Demand Supply Analysis

7.2.    Import Export Analysis

7.3.    Value Chain Analysis

7.4.    PESTEL Analysis

7.4.1.Political Factors

7.4.2.Economic System

7.4.3.Social Implications

7.4.4.Technological Advancements

7.4.5.Environmental Impacts

7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5.    Porter’s Five Forces Analysis

7.5.1.Supplier Power

7.5.2.Buyer Power

7.5.3.Substitution Threat

7.5.4.Threat from New Entrant

7.5.5.Competitive Rivalry

8.       Market Dynamics

8.1.      Growth Drivers

8.2.      Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1.    Clinical Trials

9.2.    Patent Landscape

9.3.    Regulatory Approvals

9.4.    Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.  Competition Matrix of Top Five Market Leaders

10.2.  Market Revenue Analysis of Top Five Market Leaders (in %, 2023)

10.3.  Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.  SWOT Analysis (For Five Market Players)

10.5.  Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.    Pfizer Inc.

13.1.1.   Company Details

13.1.2.   Key Management Personnel

13.1.3.   Products & Services

13.1.4.   Financials (As reported)

13.1.5.   Key Market Focus & Geographical Presence

13.1.6.   Recent Developments

13.2.    Sanofi-Aventis LLC

13.3.    Orgenesis Biotech Company

13.4.    Teva Pharmaceutical Industries Ltd.

13.5.    Verrica Pharmaceuticals

13.6.    Merck & Co., Inc

13.7.    Cipla Ltd.

13.8.    GlaxoSmithKline Plc

13.9.    Phio Pharmaceuticals Corp.

13.10. Taro Pharmaceutical Industries Ltd.

13.11. Mylan N.V.

13.12. Bausch Health Companies, Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.   Strategic Recommendations

15.   About Us & Disclaimer

List of Figures :

Figure 1. Global Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 2. Global Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 3. Global Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 4. Global Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 5. Global Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 6. Global Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 7. Global Genital Warts Market Share (%), By Region, 2017-2031F

Figure 8. North America Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 9. North America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 10. North America Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 11. North America Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 12. North America Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 13. North America Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 14. North America Genital Warts Market Share (%), By Country, 2017-2031F

Figure 15. United States Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 16. United States Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 17. United States Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 18. United States Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 19. United States Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 20. United States Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 21. Canada Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 22. Canada Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 23. Canada Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 24. Canada Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 25. Canada Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 26. Canada Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 27. Mexico Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 28. Mexico Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 29. Mexico Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 30. Mexico Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 31. Mexico Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 32. Mexico Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 33. Europe Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 34. Europe Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 35. Europe Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 36. Europe Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 37. Europe Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 38. Europe Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 39. Europe Genital Warts Market Share (%), By Country, 2017-2031F

Figure 40. Germany Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 41. Germany Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 42. Germany Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 43. Germany Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 44. Germany Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 45. Germany Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 46. France Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 47. France Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 48. France Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 49. France Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 50. France Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 51. France Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 52. Italy Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 53. Italy Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 54. Italy Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 55. Italy Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 56. Italy Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 57. Italy Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 58. United Kingdom Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 59. United Kingdom Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 60. United Kingdom Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 61. United Kingdom Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 62. United Kingdom Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 63. United Kingdom Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 64. Russia Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 65. Russia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 66. Russia Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 67. Russia Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 68. Russia Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 69. Russia Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 70. Netherlands Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 71. Netherlands Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 72. Netherlands Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 73. Netherlands Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 74. Netherlands Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 75. Netherlands Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 76. Spain Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 77. Spain Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 78. Spain Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 79. Spain Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 80. Spain Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 81. Spain Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 82. Turkey Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 83. Turkey Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 84. Turkey Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 85. Turkey Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 86. Turkey Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 87. Turkey Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 88. Poland Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 89. Poland Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 90. Poland Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 91. Poland Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 92. Poland Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 93. Poland Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 94. South America Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 95. South America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 96. South America Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 97. South America Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 98. South America Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 99. South America Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 100. South America Genital Warts Market Share (%), By Country, 2017-2031F

Figure 101. Brazil Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 102. Brazil Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 103. Brazil Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 104. Brazil Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 105. Brazil Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 106. Brazil Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 107. Argentina Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 108. Argentina Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 109. Argentina Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 110. Argentina Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 111. Argentina Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 112. Argentina Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 113. Asia-Pacific Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 114. Asia-Pacific Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 115. Asia-Pacific Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 116. Asia-Pacific Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 117. Asia-Pacific Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 118. Asia-Pacific Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 119. Asia-Pacific Genital Warts Market Share (%), By Country, 2017-2031F

Figure 120. India Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 121. India Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 122. India Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 123. India Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 124. India Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 125. India Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 126. China Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 127. China Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 128. China Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 129. China Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 130. China Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 131. China Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 132. Japan Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 133. Japan Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 134. Japan Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 135. Japan Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 136. Japan Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 137. Japan Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 138. Australia Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 139. Australia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 140. Australia Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 141. Australia Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 142. Australia Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 143. Australia Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 144. Vietnam Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 145. Vietnam Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 146. Vietnam Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 147. Vietnam Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 148. Vietnam Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 149. Vietnam Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 150. South Korea Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 151. South Korea Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 152. South Korea Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 153. South Korea Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 154. South Korea Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 155. South Korea Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 156. Indonesia Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 157. Indonesia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 158. Indonesia Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 159. Indonesia Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 160. Indonesia Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 161. Indonesia Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 162. Philippines Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 163. Philippines Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 164. Philippines Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 165. Philippines Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 166. Philippines Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 167. Philippines Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 168. Middle East & Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 169. Middle East & Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 170. Middle East & Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 171. Middle East & Africa Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 172. Middle East & Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 173. Middle East & Africa Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 174. Middle East & Africa Genital Warts Market Share (%), By Country, 2017-2031F

Figure 175. Saudi Arabia Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 176. Saudi Arabia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 177. Saudi Arabia Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 178. Saudi Arabia Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 179. Saudi Arabia Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 180. Saudi Arabia Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 181. UAE Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 182. UAE Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 183. UAE Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 184. UAE Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 185. UAE Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 186. UAE Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 187. South Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F

Figure 188. South Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F

Figure 189. South Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F

Figure 190. South Africa Genital Warts Market Share (%), By Treatment, 2017-2031F

Figure 191. South Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F

Figure 192. South Africa Genital Warts Market Share (%), By End-user, 2017-2031F

Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What are the major drivers influencing the growth of the global genital warts market?

arrowup
Heart

Global E-bike Battery Market Assessment, Opportunities and Forecast, 2017-2031F

The increased popularity of e-bikes along with the increasing adoption of compact vehicles for adventure sport and exploration is propelling the market expansion. ....Read More

Published on

April 2024

4,500

Heart

Global Chloroxylenol Market Assessment, Opportunities and Forecast, 2017-2031F

Global chloroxylenol market is expected to experience significant growth over the forecast period owing to the antimicrobial properties of chloroxylenol, increasing emphasis on maintaining skin health and personal hygiene, and growing threat of surgi....Read More

Published on

April 2024

4,500

Heart

Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F

Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.....Read More

Published on

April 2024

4,500

Heart

Global Magnesium Citrate Market Assessment, Opportunities and Forecast, 2017-2031F

Global magnesium citrate market will witness significant growth over the forecast period owing to rapid expansion of the pharmaceutical sector and increasing research and development activities.....Read More

Published on

April 2024

4,500

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979